Dylann Cohn-Emery

Articles

Adjuvant Canakinumab Misses DFS Primary End Point in NSCLC

September 12th 2022

Patients with completely resected non–small cell lung cancer did not derive a significant benefit with adjuvant canakinumab vs placebo.

Neoadjuvant Nivolumab/Ipilimumab Elicits Promising Pathologic Responses in dMMR Colon Cancer

September 11th 2022

Four weeks of treatment with nivolumab plus ipilimumab elicited major pathologic responses in 95% of patients with mismatch repair–deficient colon cancer.

Isatuximab Plus Kd Demonstrates Deep Responses in Relapsed Multiple Myeloma

August 27th 2022

The addition of isatuximab to carfilzomib and dexamethasone elicited a clinically meaningful improvement in depth of response in patients with relapsed multiple myeloma.

Adagrasib Delivers Durable CNS-Specific Activity in KRAS G12C+ NSCLC

June 7th 2022

Adagrasib led to an intracranial objective response rate of 32% and a median intracranial duration of response that was not reached in patients with KRAS G12C–mutant non–small cell lung cancer and active, untreated CNS metastases, according to findings from the KRYSTAL-1 trial.

Frontline Nivolumab/Ipilimumab Plus Chemotherapy Sustains Survival Benefit in Metastatic NSCLC

June 6th 2022

Patients with metastatic non–small cell lung cancer treated with first-line nivolumab and ipilimumab plus chemotherapy experienced prolonged benefit in overall survival compared with those who received chemotherapy alone.

Updated ENZAMET Data Underscore Long-term OS Benefit With Enzalutamide in mHSPC

June 5th 2022

The addition of enzalutamide vs a conventional nonsteroidal antiandrogen agent to testosterone suppression continued to provide clinically meaningful improvements in overall survival in patients with metastatic hormone-sensitive prostate cancer.

BTX-1188 Demonstrates Safety Benefits, Enters Phase 1 Trials in AML and Solid Tumors

June 4th 2022

BTX-1188, a first-in-class oral molecular glue, is undergoing investigation in phase 1 clinical trials in patients with solid tumors or acute myeloid leukemia, after preclinical trials supported its potential safety benefits in this population and demonstrated its high sensitivity in Myc-driven cancer cell lines.

Tislelizumab Plus Nab-Paclitaxel Yields Preliminary Efficacy in NMBIC

May 18th 2022

The combination of tislelizumab plus nab-paclitaxel demonstrated benefit and a tolerable safety profile in patients with high-risk non–muscle invasive bladder cancer.

Neoadjuvant Tislelizumab/Nab-Paclitaxel Combo Produces Early Activity in MIBC

May 16th 2022

The combination of neoadjuvant tislelizumab and nab-paclitaxel elicited a high rate of pathologic complete response in patients with muscle-invasive bladder cancer, according to preliminary findings from the phase 2 TRUCE-01 trial.

JSP191 Plus Fludarabine and Low-Dose Irradiation Produces Promising Early Data in MDS/AML

April 27th 2022

The combination of JSP191, fludarabine, and low-dose total body irradiation demonstrated facilitation of full donor myeloid chimerism, clearance of minimal residual disease, and a tolerable safety profile in patients with myelodysplastic syndrome or acute myeloid leukemia.

SOT101 Plus Pembrolizumab Elicits Encouraging Efficacy in Advanced Solid Tumors

April 13th 2022

The addition of SOT101, an interleukin-2/IL-15 Rβγ superagonist, to Pembrolizumab generated a clinical benefit and encouraging safety data in patients with advanced solid tumors.

Frontline Nivolumab/Cabozantinib Combo Maintains Long-Term OS Benefit in RCC

February 19th 2022

The combination of nivolumab plus cabozantinib elicited a continued survival benefit compared with sunitinib in patients with untreated clear cell metastatic or advanced renal cell carcinoma.

Pembrolizumab Plus BSC Produces Improved OS in Advanced HCC

January 21st 2022

The combination of pembrolizumab plus best supportive care elicited improved overall survival and overall response rates as second-line therapy in patients from Asia with advanced hepatocellular carcinoma.

Toxicity Burden Decreased With Acalabrutinib Vs Ibrutinib in CLL

December 14th 2021

Acalabrutinib demonstrated a lower incidence of cardiovascular-related toxicities and a lower overall toxicity burden compared with ibrutinib in patients with chronic lymphocytic leukemia.

Phase 3 Trial Set to Evaluate Venetoclax Plus Acalabrutinib or Obinutuzumab in Treatment-Naive CLL/SLL

December 12th 2021

The combinations of venetoclax plus acalabrutinib or obinutuzumab will be evaluated in the phase 3 MAJIC trial.

Likelihood of Pathologic CR After Neoadjuvant Chemo is Not Significantly Affected by Race in Breast Cancer

December 10th 2021

Pathologic complete response and event-free survival was not found to be significantly affected by race among patients with high-risk breast cancer who received neoadjuvant chemotherapy; however, disparities were observed among patients who did not achieve a pCR.

Nivolumab/Cabozantinib Combo Yields Efficacy Regardless of Prior Nephrectomy in RCC

September 17th 2021

Nivolumab and cabozantinib demonstrated significant benefits in progression-free survival and objective response rate for patients with renal cell carcinoma regardless of whether they had a prior nephrectomy.

Challenges Remain in Treatment of Accelerated Phase Myeloproliferative Neoplasms

September 10th 2021

Treating patients with accelerated phase myeloproliferative neoplasm is an ongoing therapeutic challenge, due to the lack of standard treatment approaches, according to an expert.

Future of PV Treatments Centers Around More Tailored Approaches

September 9th 2021

Future treatment approaches for patients with polycythemia vera (PV) should center around adapting therapy using the available criteria, and eventually finding new targets.

HER2 Positivity at Diagnosis Shows Better PFS Benefit With HER2-Based Therapies Vs Negative Status in Breast Cancer

July 12th 2021

The median progression-free survival benefit experienced by patients with metastatic breast cancer who were HER2 positive at initial diagnosis and who were receiving standard HER2-directed therapies proved to be more favorable than what was reported in those who were HER2 negative and switched to HER2 positive status.